Business Wire

Calyx Global Report Shows Scrutiny of the Carbon Market May Be Paying Off

Share

An analysis of the state of quality in the voluntary carbon market gives early indications that the market is moving towards higher integrity. The report, by carbon credit ratings platform Calyx Global, integrates data on market trends with Calyx Global’s 500+ ratings to provide unique insights on how efforts to improve market integrity are faring.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611593881/en/

Source includes data from Calyx Global’s ratings of over 500 carbon projects. In addition, data was used from the UC Berkeley database (Barbara K. Haya, Aline Abayo, Ivy S. So., Micah Elias. (2024, May). Voluntary Registry Offsets Database v11, Berkeley Carbon Trading Project, University of California, Berkeley), which includes the four major registries – ACR, CAR, Gold Standard and VCS. (Graphic: Business Wire)

After widespread pressure and scrutiny from the media and academia, many market actors have moved to address issues with the quality of carbon credits. This report tracks the effectiveness of those efforts.

“We wanted to start tracking quality, recognizing that the voluntary carbon market is starting to mature,” said Calyx Global Co-founder Donna Lee. She added, “The quicker we improve carbon credit quality and restore confidence, the more effective companies can be at addressing climate change.”

Key findings from the report include:

  • The issuance of lowest-grade credits has dropped nearly 50% as a proportion of total issued credits to date in 2024.
  • Quality updates related to improving the rules and requirements for credit generation have not yet made their way onto the active market.
  • While benefits “beyond carbon” are attractive to buyers, it is a search for higher GHG integrity that is driving trends in the market today.

To learn about these trends and more, download “The State of Quality in the Voluntary Carbon Market” report or register for the June 26, 2024 webinar.

About the company

Calyx Global is a carbon credit ratings platform that helps organizations find carbon credits with confidence. Rigorous ratings and analysis ensure that carbon buyers can do good for people and the planet. From nature-based solutions to emerging technologies, Calyx Global leads the market with over 500 rated projects (and counting). To learn more, visit www.calyxglobal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611593881/en/

Contacts

Media contact
Cheryl Sansonetti
marketing@calyxglobal.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia24.6.2024 12:30:00 EEST | Press release

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it received the Whitsett Award for highest scoring abstracts from the Neonatal and Developing Lung Executive Committee at the American Thoracic Society (ATS) 2024 International Conference. The abstract is titled “Randomized Blinded Phase 1b Study Demonstrates Safety and Tolerability of Zelpultide Alfa (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD).” Thirty-seven infants, born at 23 weeks to 28 weeks and 6 days, were enrolled in the study in the US and Europe. No dose limiting toxicities were found while indications of efficacy were observed. As many as 2.5 million very preterm infants globally are at risk of developing BPD from lung damage caused by mechanical ventilation and oxygen support. Babies who develop BPD can suffer life

REPLY: AIRA Challenge 2024 Prize awarded to Roboverse Reply for Mobile Robot Control via VR Glasses24.6.2024 11:00:00 EEST | Press release

Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. The competition invited world-leading experts to develop innovative solutions for enabling the remote control of mobile robots during autonomous inspections in production environments. Roboverse Reply’s platform demonstrates how Artificial Intelligence and human expertise can be combined to tackle challenging industrial tasks in real-world applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624606163/en/ Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. (Graphic: Business Wire) The final of the AIRA Challenge took place for the second time at ACHEMA, the world's largest trade fair fo

Takeda Announces Approval of LIVTENCITY ® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies24.6.2024 10:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1 “We are pleased by the approval of LIVTENCITY in Japan, which will provide the transplant community with a new option for treatment of post-transplant CMV infection in patients refractory to other therapies,” said Yasushi Kajii, Head, R&D Japan Region at Takeda. “A diagnosis of CMV infection can be particularly challenging for patients, and serious complications such as increased organ rejection and hospitalization rates can occur, when not successfully treated. We believe LIVTENCITY has the potential to help address the challenges faced by people with post-transplant CMV and

Megaport and Lufthansa Systems Announce Landmark Partnership to Accelerate Airline Digital Transformation24.6.2024 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), the global leading Network as a Service (NaaS) provider, and Lufthansa Systems, a leading aviation IT provider, today announced a new partnership that will accelerate digital transformation in the aviation industry. The strategic partnership will see Lufthansa Systems leverage Megaport’s global Software Defined Network (SDN) to securely and reliably move the global aviation cloud from a single cloud to multiple clouds by moving core routing from cloud to Megaport. Megaport will also facilitate a secure aviation customer landing zone to expedite peering with other airlines and exchanging data. Lufthansa Systems provides IT services to over 350 airlines worldwide. Its Global Aviation Cloud initiative aims to virtualise mission-critical airline applications and transition them to the cloud. Using Megaport’s private connectivity from resilient data centres, virtual firewalls, and virtual routing, Lufthansa Systems can securely and reliably connect

Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)24.6.2024 09:00:00 EEST | Press release

Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, based in Paris and Munich, announced today the completion of the second closing part of Series B financing round of Vico Therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240623484065/en/ Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing therapies for severe neurological diseases. Its lead program VO659 is currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease, devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available. Seroba joined the consortium of investors leading the planned second closing of the Series B financi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye